About AmbioPharm
AmbioPharm is a Healthcare company based in North Augusta (United States) founded in 2006, and was acquired by Corden Pharma in May 2026. CDMO and analytical services for peptide development are provided. AmbioPharm has raised $24 million across 2 funding rounds from investors including The Carlyle Group and Corden Pharma. Its website ambiopharm.com draws about 15 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development. Its competitors include Ocelot Bio, Aperiam Bio and vivitide; 2 of its 3 listed competitors have raised funding.
Company details
AmbioPharm is the contract manufacturer of peptides and biopharmaceuticals which also offers GMP services like Peptide API production and non-GMP process development services like GLP-grade peptide supply for pre-clinical applications, custom peptides and non-peptidic small molecules for pre-clinical in-vitro, medicinal, and toxicology programs. It also provides vaccine development services for developing antigenic sequences, single antigens, Multi-Antigenic-Peptides (MAPS), and multiple peptide vaccine cocktails. In parallel, it also provides analytical and process development tools that monitor the process for side reactions, purity checks, API control and process minimization. The company also offers services for organic conjugation to small molecules, proteins, toxoids, antifungals, KLH, and PEG. They claim to have expertise in a wide range of halogenated chemicals, with core competencies in fluorination of APIs and advanced intermediates.
- Headquarters North Augusta, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ambiopharm.com
- Social LinkedIn X YouTube
- Acquired by Corden Pharma (May 2026)
- Total Equity Funding$24M (USD)
in 2 rounds
- InvestorsThe Carlyle Group
& 1 more
- Acquired byCorden Pharma
(May 2026)
Apps and channels of AmbioPharm
its YouTube channel AmbioPharm, Inc. has 42 subscribers and 6 videos.
Videos from AmbioPharm
The most watched videos on AmbioPharm's YouTube channel, AmbioPharm, Inc. (42 subscribers). Click a video to play it here.
More on AmbioPharm, Inc..
Funding Insights of AmbioPharm
AmbioPharm has successfully raised a total of $24M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24M
- Total Rounds 2
- First Round $24M
(Nov 2014)
- Investors Count 1
All 2 funding rounds of AmbioPharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | Series B | – | The Carlyle Group | – | |
| Nov 2014 | $24M | Series B | – | – | – |
2 investors in total: 2 institutional.
Investors in AmbioPharm
AmbioPharm has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include The Carlyle Group and Corden Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward multiple sectors. | 1986 | carlyle.com | ||
CDMO offering its services for small molecules, peptides, lipids and carbohydrates | 2006 | cordenpharma.com | Plankstadt, Germany |
Investor details for AmbioPharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AmbioPharm
17 people are tracked at AmbioPharm (10 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Juncai Bai | Executive Director, Founder, Chairman of the Board & CEO | Leadership |
Stephen John Kiel | CFO | Leadership |
Mukesh Patel | VP of Manufacturing | Leadership |
Mark Brown | Vice President Of Accounting | Leadership |
Gary Hu | Senior Vice President of Sales, Asia | Leadership |
Snow Wang | Director of Finance and HR | Leadership |
ジョージ進伍 山本 | Director of Sales, Japan/Asia, Business Development | Leadership |
Sammie Liu Choe | VP of Finance and HR | Leadership |
Kevin South | Director Of Manufacturing Operations | Leadership |
Guoqing Zhang | VP of Manufacturing & Process Development | Leadership |
Gary T.K. Hu | SVP, Sales, Asia | Team |
Brant Zell | SVP of Quality | Team |
angela liu | HR | Team |
Alexandra Vega | Human Resources | Team |
Teresa Cheek | HR & Recruiting Supervisor At Ambiopharm | Team |
AKHIL P. | GXP Validation Engineer | Team |
Cristina Brennan | Marketing Lead | Team |
Complete people profiles for AmbioPharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AmbioPharm
4 dated milestones of AmbioPharm across 20 years, from founding to its latest funding, stage changes and deals.
- Founded AmbioPharm is founded.
- Funding First funding round of $24.0M.
- Funding Latest funding round, Series B,.
- Exit Acquired by Corden Pharma.
Competitors of AmbioPharm
AmbioPharm has 3 listed competitors in our database, 2 of them funded. They include Ocelot Bio, Aperiam Bio and vivitide.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ocelotbio.com | 2020 | San Diego, United States | $36M | Ocelot Bio is a CDMO specializing in peptide manufacturing services. | ||
| aperiambio.com | 2019 | United States | $13M | Industrial and therapeutic proteins are manufactured by Aperiam Bio. | ||
| vivitide.com | 1983 | Gardner, United States | 94 | Drug development services for neoantigen peptides and antibodies are provided. |
Detailed competitors of AmbioPharm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AmbioPharm
The website of AmbioPharm (ambiopharm.com) receives about 15.1K visits a month and ranks #1,550,315 among all websites worldwide, #2,055 in Biotechnology and Pharmaceuticals.
- Monthly visits15.1K
▲ 15.9% vs previous month
- Unique visitors6K
per month
- Global rank#1,550,315
among all websites
- Category rank#2,055
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.8
- Average visit1 min 15 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with AmbioPharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bachem.com | 100% | 167.9K | #280,794 | View details | |
| sterlingpharmasolutions.com | 99% | 12.2K | #2,060,032 | View details | |
| zealandpharma.com | 93% | 25.2K | #1,273,571 | View details | |
| cordenpharma.com | 93% | 26.2K | #789,402 | View details | |
rootsanalysis.com | rootsanalysis.com | 93% | #710,325 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for AmbioPharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as AmbioPharm (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ambiopharm
Complete news archive for AmbioPharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AmbioPharm
AmbioPharm was founded in 2006 and raised its 1st funding round 8 years after it was founded.
AmbioPharm is headquartered in North Augusta, United States. It is registered at North Augusta, South Carolina, United States.
AmbioPharm is a funded company, having raised a total of $24M across 2 funding rounds to date. The company's 1st funding round was a Series B of $24M, raised on Nov 2014.
AmbioPharm is the contract manufacturer of peptides and biopharmaceuticals which also offers GMP services like Peptide API production and non-GMP process development services like GLP-grade peptide supply for pre-clinical applications, custom peptides and non-peptidic small molecules for pre-clinical in-vitro, medicinal, and toxicology programs. It also provides vaccine development services for developing antigenic sequences, single antigens, Multi-Antigenic-Peptides (MAPS), and multiple peptide vaccine cocktails. In parallel, it also provides analytical and process development tools that monitor the process for side reactions, purity checks, API control and process minimization. The company also offers services for organic conjugation to small molecules, proteins, toxoids, antifungals, KLH, and PEG. They claim to have expertise in a wide range of halogenated chemicals, with core competencies in fluorination of APIs and advanced intermediates.
AmbioPharm's top competitors include vivitide, Aperiam Bio and Ocelot Bio.
AmbioPharm has 2 investors. Key investors include The Carlyle Group, and Corden Pharma.
Yes. AmbioPharm was acquired by Corden Pharma in May 2026.